A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Phase 2 Completed
40 enrolled 15 charts
Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation
Phase NA Completed
20 enrolled 11 charts
Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
Phase 1/2 Completed
87 enrolled 24 charts
Off-the-shelf NK Cells + SCT for Myeloid Malignancies
Phase 2 Completed
24 enrolled 9 charts
A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors
Phase 2 Completed
78 enrolled 13 charts
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies
Phase 2 Completed
62 enrolled 15 charts
Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation
Phase 2 Completed
43 enrolled 10 charts
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
Phase 1/2 Completed
34 enrolled 18 charts
Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor
Phase 2 Completed
28 enrolled 10 charts
A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative
Phase 1/2 Completed
27 enrolled 11 charts
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies
Phase 2 Completed
25 enrolled 9 charts
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase 2 Completed
35 enrolled 14 charts
Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
Phase 1/2 Completed
64 enrolled 13 charts
Expanded Access Protocol Thymus Transplantation
Phase 4 Completed
11 enrolled 10 charts
Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor
Phase NA Completed
44 enrolled 8 charts
CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies
Phase 1/2 Completed
27 enrolled 12 charts
1703/1801
Phase 3 Completed
431 enrolled 44 charts
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children
Phase 2 Completed
20 enrolled 16 charts
Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)
Phase 2 Completed
11 enrolled 12 charts
A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan
Phase 2 Completed
41 enrolled 10 charts
Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
Phase 1/2 Completed
54 enrolled 18 charts
MK-7110-002
Phase 2 Completed
44 enrolled 27 charts
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant
Phase 2 Completed
38 enrolled 11 charts
Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation
Phase 2 Completed
22 enrolled 15 charts
Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer
Phase 2 Completed
5 enrolled 10 charts
Donor Stem Cell Transplant Followed by Cyclophosphamide in Treating Patients With Hematological Diseases
Phase 2 Completed
27 enrolled 13 charts
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma
Phase 2 Completed
6 enrolled 10 charts
Immunotherapy of the Paraneoplastic Syndromes
Phase NA Completed
26 enrolled 6 charts
Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention
Phase 3 Completed
101 enrolled 28 charts
Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning
Phase 2 Completed
201 enrolled 12 charts
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 2 Completed
68 enrolled 8 charts
PROACTIVE: Preventing Acute/Chronic GVHD With TocIlizumab Combined With GVHD Prophylaxis Post allogEneic Transplant
Phase 2 Completed
29 enrolled 9 charts
Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Phase 2 Completed
66 enrolled 12 charts
BMT CTN 0402
Phase 3 Completed
304 enrolled 20 charts
Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease
Phase 1/2 Completed
38 enrolled 12 charts
Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease
Phase NA Completed
2 enrolled 10 charts
Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies
Phase 2 Completed
117 enrolled 27 charts
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia
Phase 2 Completed
68 enrolled 11 charts
TCR-α/β and CD19 Depleted Stem Cell Grafts From Haplo Donors for HSCT in Relapsed Lymphoma
Phase NA Completed
11 enrolled 13 charts
Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies
Phase 1/2 Completed
53 enrolled 17 charts
Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Phase 3 Completed
256 enrolled 13 charts
Myeloablative Haploidentical BMT With Post-transplant Cyclophosphamide for Pediatric Patients With Hematologic Malignancies
Phase 2 Completed
35 enrolled 18 charts
Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia
Phase 1/2 Completed
37 enrolled 20 charts
Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia
Phase 2 Completed
96 enrolled 15 charts
Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation
Phase 2 Completed
76 enrolled 16 charts
Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies
Phase 2 Completed
22 enrolled 5 charts
Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)
Phase 2 Completed
20 enrolled 9 charts
Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia
Phase 2 Completed
158 enrolled 10 charts
Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies
Phase 2 Completed
60 enrolled 15 charts
Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide
Phase 2 Completed
176 enrolled 18 charts